Onconetix, Inc. Operating Cash Flow
Onconetix, Inc. (ONCO) reported Operating Cash Flow of -$4.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Onconetix, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$1.92M.
- Onconetix, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$2.12M.
- Onconetix, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.09M.
- Onconetix, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.18M.
- Onconetix, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$9.68M.
- Onconetix, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$10.50M.
- Onconetix, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$13.58M.
- Onconetix, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$8.68M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$4.04M 10-Q · filed 2026-08-13 | -$7.13M derived: sum of 3 quarters · filed 2026-08-13 | -$10.31M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$2.12M 10-Q · filed 2026-05-13 | -$5.21M derived: sum of 2 quarters · filed 2026-05-13 | -$8.39M derived: sum of 3 quarters · filed 2026-05-13 | -$9.80M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$3.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$6.27M derived: sum of 2 quarters · filed 2026-03-13 | -$7.68M derived: sum of 3 quarters · filed 2026-08-13 | -$9.68M 10-K · filed 2026-03-13 | ||||
| 2025-09-30 | -$3.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$4.59M derived: sum of 2 quarters · filed 2026-08-13 | -$6.59M 10-Q · filed 2025-11-13 | -$7.51M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$3.41M 10-Q · filed 2026-08-13 | -$4.33M derived: sum of 3 quarters · filed 2026-08-13 | -$5.47M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$2.00M 10-Q · filed 2026-05-13 | -$2.92M derived: sum of 2 quarters · filed 2026-05-13 | -$4.06M derived: sum of 3 quarters · filed 2026-05-13 | -$7.26M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | -$917.65K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$2.06M derived: sum of 2 quarters · filed 2026-03-13 | -$5.26M derived: sum of 3 quarters · filed 2026-03-13 | -$10.50M 10-K · filed 2026-03-13 | ||||
| 2024-09-30 | -$1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$4.35M derived: sum of 2 quarters · filed 2025-11-13 | -$9.58M 10-Q · filed 2025-11-13 | -$13.89M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$3.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$8.43M 10-Q · filed 2025-08-14 | -$12.74M derived: sum of 3 quarters · filed 2025-08-14 | -$15.78M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | -$5.23M 10-Q · filed 2025-06-12 | -$9.54M derived: sum of 2 quarters · filed 2025-06-12 | -$12.58M derived: sum of 3 quarters · filed 2025-06-12 | -$14.40M derived: sum of 4 quarters · filed 2025-06-12 | ||||
| 2023-12-31 | -$4.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | -$7.35M derived: sum of 2 quarters · filed 2025-06-02 | -$9.17M derived: sum of 3 quarters · filed 2025-06-02 | -$13.58M 10-K · filed 2025-06-02 | ||||
| 2023-09-30 | -$3.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-10 | -$4.86M derived: sum of 2 quarters · filed 2024-12-10 | -$9.27M 10-Q · filed 2024-12-10 | -$12.07M derived: sum of 4 quarters · filed 2024-12-10 | ||||
| 2023-06-30 | -$1.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-29 | -$6.23M 10-Q · filed 2024-08-29 | -$9.03M derived: sum of 3 quarters · filed 2024-08-29 | -$10.84M derived: sum of 4 quarters · filed 2024-08-29 | ||||
| 2023-03-31 | -$4.41M 10-Q · filed 2024-05-20 | -$4.45M 10-Q · filed 2023-05-12 | -$7.21M derived: sum of 2 quarters · filed 2024-05-20 | -$9.03M derived: sum of 3 quarters · filed 2024-05-20 | -$12.20M derived: sum of 4 quarters · filed 2024-05-20 | |||
| 2022-12-31 | -$2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | -$4.61M derived: sum of 2 quarters · filed 2024-04-11 | -$7.79M derived: sum of 3 quarters · filed 2024-04-11 | -$8.68M 10-K · filed 2024-04-11 | -$8.70M 10-K · filed 2023-03-09 | |||
| 2022-09-30 | -$1.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | -$4.99M derived: sum of 2 quarters · filed 2023-11-17 | -$5.88M 10-Q · filed 2023-11-17 | -$5.90M 10-Q · filed 2022-11-14 | -$6.55M derived: sum of 4 quarters · filed 2023-11-17 | |||
| 2022-06-30 | -$3.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-10-20 | -$4.06M 10-Q · filed 2023-10-20 | -$4.07M 10-Q · filed 2022-08-15 | -$4.74M derived: sum of 3 quarters · filed 2023-10-20 | -$5.47M derived: sum of 4 quarters · filed 2023-10-20 | |||
| 2022-03-31 | -$886.09K 10-Q · filed 2023-05-12 | -$1.56M derived: sum of 2 quarters · filed 2023-05-12 | -$2.29M derived: sum of 3 quarters · filed 2023-05-12 | -$2.67M derived: sum of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | -$674.40K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$1.40M derived: sum of 2 quarters · filed 2023-03-09 | -$1.79M derived: sum of 3 quarters · filed 2023-03-09 | -$2.04M 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | -$730.48K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$1.11M derived: sum of 2 quarters · filed 2022-11-14 | -$1.37M 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | -$382.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$639.35K 10-Q · filed 2022-08-15 | ||||||
| 2021-03-31 | -$256.55K 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |